Breakingviews – Pfizer can recover from its post-Covid fatigue – Reuters

Vials containing Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed after being used during the second booster vaccination program held at a church, in Santiago, Chile, February 7, 2022. REUTERS/Ivan Alvarado Acquire Licensing Rights

NEW YORK, Oct 31 (Reuters Breakingviews) - Its hard to imagine Pfizer (PFE.N), which invented one of the main vaccines that protect against Covid-19, is worth less now than it was before the pandemic. Yet thats what the pharmaceutical companys $170 billion market capitalization suggests, with year-long fears about declining vaccine demand coming to fruition in third-quarter results. Its an over-reaction, even if Pfizers Covid therapies were to prove worthless.

Pfizer reported plummeting demand for its Covid vaccines and treatments, with an overall revenue decline of over 40% compared to last year, and a $2.4 billion loss that included a $5.6 billion charge for Covid inventory write-offs. Pfizer now thinks 2023 revenue from shots and pills for the disease will total about $12.5 billion, over a 75% decrease from last year.

Thats more than accounted for in the stock. Pfizers non-Covid revenue this year should be around $47 billion and is growing around 7% a year. Peers trade at around 5 times sales, and if Pfizer did too its enterprise value would be about $235 billion. Instead its almost 20% less, and the stock is worth one-fifth less than it was at the end of 2019. Whats more, Pfizer has made a string of cashacquisitions totaling about $70 billion since 2020, suggesting the pandemic should have left it stronger, even if its line-up of Covid defenses is getting only weaker. (By Robert Cyran)

Follow @Breakingviews on X

Capital Calls More concise insights on global finance:

Brookfields climate deal may run out of energy read more

BYDs Halloween bonanza spooks rivals read more

McDonalds menu stocks up on global variations read more

Vodafone will struggle to get clean exit in Spain read more

Aussie tycoon doubles down as lithium spoiler read more

Editing by John Foley and Aditya Sriwatsav

Our Standards: The Thomson Reuters Trust Principles.

Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

More here:

Breakingviews - Pfizer can recover from its post-Covid fatigue - Reuters